RHHBY Revenue Growth (YoY) Analysis
Higher than 9% of Healthcare sector peers
Updated 2843h ago·SEC filings & market data
Key Takeaway
RHHBY (RHHBY) has a Revenue Growth (YoY) of -1.1% as of May 2026.
Sector Performance
9th percentileRHHBY
-1.1%
Sector Median
8.9%
Sector Avg
12.6%
Deep Analysis
RHHBY (RHHBY) has a Revenue Growth (YoY) of -1.1% as of May 2026.
This places RHHBY in the 9th percentile of the Healthcare sector, which has a median Revenue Growth (YoY) of 8.9% and a sector average of 12.6%. RHHBY's Revenue Growth (YoY) is 112.4% below the sector median, a significant divergence that warrants closer examination. In context: Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Frequently Asked Questions
What does the Revenue Growth (YoY) tell investors about RHHBY?
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
How is the Revenue Growth (YoY) calculated?
Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.
How does RHHBY's Revenue Growth (YoY) compare to its sector?
RHHBY's Revenue Growth (YoY) of -1.1% compares to a Healthcare sector median of 8.9%, placing it in the 9th percentile.
Who are RHHBY's closest peers by Revenue Growth (YoY)?
The closest Healthcare peers by Revenue Growth (YoY) include: A (10.0%), ABT (7.8%), DGX (10.2%), RMD (10.8%), CAH (11.0%).
Learn More About Revenue Growth (YoY)
The Formula
(Revenue_t - Revenue_t-4) / Revenue_t-4
Why It Matters
Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.
Master RHHBY's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full RHHBY research report →RHHBY
-1.1%
Sector Median
8.9%
Sector Avg
12.6%
How RHHBY's Revenue Growth (YoY) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.